GlassScriptPhysician profile
Gary Lee Tunell
NPI 1528033453
$2,714.99
in general payments reported to CMS, 2019-2025
33 companies · $23.21 in 2025
The $23.21 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,619 · 2020: $73.23 · 2025: $23.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $488.58 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $284.91 | 2019 | |
| Genzyme Corporation | $195.89 | 2019 | |
| Acadia Pharmaceuticals INC | $149.88 | 2019 | |
| Ucb, INC. | $148.89 | 2019 | |
| Allergan, INC. | $144.41 | 2019 | |
| Acorda Therapeutics, INC | $131.35 | 2019 | |
| Biogen, INC. | $125.12 | 2019 | |
| Emd Serono, INC. | $121.65 | 2019 | |
| Genentech USA, INC. | $96.86 | 2019 | |
| Amgen INC. | $88.17 | 2019 | |
| Merz North America, INC. | $77.98 | 2019 | |
| Greenwich Biosciences, INC. | $73.84 | 2019 | |
| Mallinckrodt Enterprises LLC | $65.42 | 2019 | |
| Tanabe Pharma America, INC. | $63.35 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $59.07 | 2019 | |
| Mdd US Operations, LLC | $57.99 | 2019 | |
| Avanir Pharmaceuticals, INC. | $56.55 | 2019 | |
| Alexion Pharmaceuticals, INC. | $51.03 | 2019 | |
| Upsher-Smith Laboratories LLC | $37.62 | 2019 | |
| Promius Pharma LLC | $32.57 | 2019 | |
| Lilly USA, LLC | $26.70 | 2019 | |
| Abbvie INC. | $23.21 | 2025 | |
| Jazz Pharmaceuticals INC. | $18.92 | 2019 | |
| Kyowa Kirin, INC. | $18.29 | 2019 | |
| Adamas Pharmaceuticals, INC. | $17.77 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.52 | 2019 | |
| Pfizer INC. | $15.43 | 2019 | |
| Ge Healthcare | $14.86 | 2020 | |
| Neurocrine Biosciences, INC. | $11.16 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$8,384.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Tunell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.